Virtu Financial LLC Sells 14,299 Shares of Selecta Biosciences, Inc. (NASDAQ:SELB)

Virtu Financial LLC cut its position in Selecta Biosciences, Inc. (NASDAQ:SELB) by 53.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,565 shares of the company’s stock after selling 14,299 shares during the quarter. Virtu Financial LLC’s holdings in Selecta Biosciences were worth $31,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SELB. UBS Group AG bought a new stake in Selecta Biosciences in the 2nd quarter valued at $91,000. New York State Common Retirement Fund bought a new stake in shares of Selecta Biosciences during the 2nd quarter valued at $176,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Selecta Biosciences during the 2nd quarter valued at $72,000. California Public Employees Retirement System bought a new stake in shares of Selecta Biosciences during the 2nd quarter valued at $390,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Selecta Biosciences during the 2nd quarter valued at $525,000. Institutional investors and hedge funds own 57.20% of the company’s stock.

A number of analysts have recently weighed in on the company. Mizuho downgraded Selecta Biosciences from a “buy” rating to a “neutral” rating and cut their target price for the company from $7.00 to $2.50 in a research report on Thursday, October 1st. HC Wainwright cut their target price on Selecta Biosciences from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, October 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Selecta Biosciences in a research report on Friday, October 9th. BidaskClub downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 10th. Finally, William Blair downgraded Selecta Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 1st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $6.29.

Shares of SELB opened at $3.27 on Friday. Selecta Biosciences, Inc. has a 12-month low of $1.42 and a 12-month high of $4.83. The business has a 50-day simple moving average of $3.20 and a two-hundred day simple moving average of $2.74. The stock has a market cap of $353.26 million, a PE ratio of -3.27 and a beta of 1.29.

Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Thursday, November 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. The firm had revenue of $4.65 million during the quarter, compared to analyst estimates of $3.75 million. As a group, equities analysts forecast that Selecta Biosciences, Inc. will post -0.55 earnings per share for the current fiscal year.

In related news, Director Timothy A. Springer purchased 2,000,000 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The stock was bought at an average price of $1.68 per share, with a total value of $3,360,000.00. Following the completion of the purchase, the director now owns 7,293,625 shares in the company, valued at approximately $12,253,290. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Peter G. Traber purchased 40,000 shares of the firm’s stock in a transaction dated Monday, December 14th. The stock was bought at an average cost of $3.24 per share, with a total value of $129,600.00. Following the purchase, the insider now owns 40,000 shares of the company’s stock, valued at approximately $129,600. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 9,101,490 shares of company stock valued at $18,461,995. Insiders own 22.40% of the company’s stock.

Selecta Biosciences Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

Featured Story: How to Use the MarketBeat Retirement Calculator

Want to see what other hedge funds are holding SELB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Selecta Biosciences, Inc. (NASDAQ:SELB).

Receive News & Ratings for Selecta Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Selecta Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.